- Home
- CRDF vs TPVG Comparison
CRDF vs TPVG Comparison
Compare CRDF & TPVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- TPVG
- Stock Information
- Founded
- CRDF 1999
- TPVG 2013
- Country
- CRDF United States
- TPVG United States
- Employees
- CRDF N/A
- TPVG N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- TPVG Other Consumer Services
- Sector
- CRDF Health Care
- TPVG Consumer Discretionary
- Exchange
- CRDF Nasdaq
- TPVG Nasdaq
- Market Cap
- CRDF 288.7M
- TPVG 286.6M
- IPO Year
- CRDF N/A
- TPVG N/A
- Fundamental
- Price
- CRDF $3.19
- TPVG $7.01
- Analyst Decision
- CRDF Strong Buy
- TPVG Hold
- Analyst Count
- CRDF 4
- TPVG 5
- Target Price
- CRDF $12.00
- TPVG $7.31
- AVG Volume (30 Days)
- CRDF 1.1M
- TPVG 357.6K
- Earning Date
- CRDF 05-01-2025
- TPVG 03-05-2025
- Dividend Yield
- CRDF N/A
- TPVG 17.19%
- EPS Growth
- CRDF N/A
- TPVG N/A
- EPS
- CRDF N/A
- TPVG 0.82
- Revenue
- CRDF $683,000.00
- TPVG $108,208,000.00
- Revenue This Year
- CRDF N/A
- TPVG N/A
- Revenue Next Year
- CRDF N/A
- TPVG $0.42
- P/E Ratio
- CRDF N/A
- TPVG $8.52
- Revenue Growth
- CRDF 39.96
- TPVG N/A
- 52 Week Low
- CRDF $2.01
- TPVG $6.44
- 52 Week High
- CRDF $6.38
- TPVG $9.73
- Technical
- Relative Strength Index (RSI)
- CRDF 34.89
- TPVG 33.35
- Support Level
- CRDF $3.65
- TPVG $7.08
- Resistance Level
- CRDF $3.88
- TPVG $7.20
- Average True Range (ATR)
- CRDF 0.25
- TPVG 0.13
- MACD
- CRDF -0.07
- TPVG -0.01
- Stochastic Oscillator
- CRDF 8.21
- TPVG 17.46
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.